Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Exploring the possibilities in Cell & Gene Therapy
- Cell and Gene Therapy


Allied Academies Conducted a Joint event on International Conference on Cell and Gene Therapy & World Congress on Clinical and Medical Microbiology during September 10-11, 2018, at Dublin, Ireland.

This report contains the summary of the two-day event with oral presentations, panel discussions and networking experiences of speakers and delegates present in the meeting. The conference brought together almost 25 delegates from over 10 different countries, specifically from Asian Subcontinent, Europe and the USA with a common goal to discuss and review the role of stem cell therapies as well as  advanced techniques in clinical and medical Microbiology and exploring latest advances and current researches in both the fields. It also set a stage for valuable cooperation among the researchers and clinicians in both the fields and towards a new approach in interdisciplinary science of Cell and Gene therapy and Microbiology.

The conference begun with the opening review of the common goal by the moderator, Ms Shirley O’Deo from Dublin, Ireland. It concluded with an explicit networking experience where the delegates took the stage to give a brief introduction about themselves and a short interview with the chairperson, Dr Vipin Rastogi  by the moderator of the event.

Opening Ceremony

Opening the conference, Ms Shirley O’Deo highlighted the theme of the event and the sessions which will be presented. The opening speech was followed by the felicitation of the Organizing Committee Members by the Chair Persons, Dr Vipin Rastogi, Senior Research Biologist, BioDefense Branch Research and Technology Directorate US ARMY–ECBC,USA. and Dr Mahony James, Professor Emeritus , Pathology and Molecular Medicine McMaster University ,Canada


The event witnessed four keynote speeches aiming on  Current challenges to bioterrorism response by Dr.Vipin K Rastogi,US ARMY,USA, In vivo engraftment of t cells transfected using solupore® is superior compared with electroporation-based systems by Dr.Shirley O’Dea, Avectas Ltd., Ireland, Early and rapid prediction for postoperative infections following percutaneous nephrolithotomy in patients with complex kidney by Dr.Chonghe Jiang, The People's Hospital of Qingyuan City, China and Intranasal vaccination with the type III secretion system (T3SS) antigen BD584 reduces both vaginal shedding of Chlamydia trachomatis and associated upper genital tract pathology by Dr. James Mahony, McMaster University, Canada followed by six regular speaker sessions by Ghada Mohammad Al-Ashmawy, Nahla E. El-Ashmawy, Tanta University, Egypt ,Róisín M Dwyer, National University of Ireland Galway, Ireland and James Mahony, McMaster University, Canada

Closing Ceremony and Networking

The two-day joint event on Clinical microbiology and cell and gene therapy ended with a vote of thanks to the coordinators, organizing committee members and all the team associated with the event. Dr Mahony james felicitated the moderator, Ms sirley odea with a very welcoming speech about her role at the event. All the delegates present in the hall were called up on stage for presenting the certificate of recognition by the chairpersons. Dr Vipin rastogi and Dr Chonghe jiang took the centre stage by explaining their views about the modern day clinical microbiology and how researchers have to work in collaboration to make it effective and accessible.

Allied Academies offers its heartfelt appreciation to Organizing Committee Members, dexterous of field, various outside experts, company representatives and is obliged to other eminent personalities who interlaced with Allied Academies and supported the conference in every aspect, without which the conference would not have been possible.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Microbiology and Cell and gene therapy research, Allied Academies would like to announce the commencement of the “2nd world congress on Microbiology and Clinical pathology” to be held during May 06-07, 2019 at Bangkok, Thailand “2nd International conference on Cell and Gene therapy” to be held during June 19-20, 2019 at Tokyo, Japan. We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of Microbiology and cell and gene therapy.

About Conference

The Allied Academies' family invites all the participants from all over the world to attend International Conference on Cell and Gene Therapy 2018 during September 10-11, 2018, in Dublin, Ireland which includes prompt keynote presentations, Oral talks, Poster presentations, Young Research Forum, E-Poster presentation and Exhibitions. 
Cell and Gene Therapy Conference hosting presentations from editors of prominent referred journals, renowned active investigators and decision makers in the field of Genetics and many related field.

Cell and Gene Therapy 2018 Conference deals with the diagnosis, prevention, and treatment & therapies of diseases of the gene specific, cell specific, organ specific and including the latest techniques in current era. Cell and Gene Therapy 2018 is an extraordinary event designed for International medical health professionals and Immunologist, Oncologist, Neurologist, Genetic researchers, many organizations and associated people of gene and cell research to facilitate the dissemination and application of research findings related to Cell and Gene.The conference invites participants from all leading universities, clinical research institutions and diagnostic companies to share their research experiences on all aspects of this rapidly expanding field and thereby, providing a showcase of the latest techniquesCell and Gene Therapy 2018 provides two days of robust discussions on methods and strategies related to management and quality improvement of Cell and Gene Therapy as well as explore new ideas and concepts on a global scale and the topics include Genomic Engineering, Biomarker, Advances in Cell and Gene Therapy, Manufacturing Innovation R&D, Immunogenetics & TransplantationFuture scope of Cell & Gene Therapy, Cell and Gene Therapy Innovation, Regenerative Medicine, and many related topics of gene and cell.

Why to attend??

With members from around the world focused on learning about 
 Cell and Gene Therapy and its advances: this is your best opportunity to reach the largest assemblage of participants from Cell and Gene Therapy community. Conduct presentations, distribute information , meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event, world-renowned speakers, the most recent techniques, developments, and the latest updates in Cell and Gene Therapy are hallmarks of this conference.

Why to Join us in Dublin, Ireland for the leading annual Cell & Gene Therapy 2018 Event 

01. Find the latest developments in Cell and Gene Therapy

02. Lectures by the world's prominent Cell and Gene Researchers and poster presentations at every career stage.
03. Network of Cell & Gene therapy with colleagues from all over the country
04. Awareness on novel tools and techniques to benefit your research

05.Promotes basic and clinical Research in Cell and Gene Therapy by facilitating recent innovations and trends in the field

Welcome Message

We are delighted to invite you a new initiative, "International Conference on Cell and Gene Therapy” during September 10-11, 2018, going to be held in Dublin, Ireland

Allied Academies Meetings invites you to the  Conference on Cell and Gene Therapy 2018 going to be held in September with the topic,"International Conference on Cell and Gene Therapy 2018” This international meet (Cell and Gene Therapy 2018) foresees several delegates including Keynote speakers, Oral presentations by prestigious speakers and publication presentations by understudies other than representatives around the globe. This gathering may be a mammoth occasion that makes a perfect stage to share aptitude tending to current advancements required in Cell and Gene Therapy. It will be an awesome open door for every one of the representatives as it gives a universal systems administration chance to team up with the world class Experts of Cell and Gene Therapy researchers and pharmaceutical field.  

About our Organization

Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies. This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).

Sessions & Tracks

1. Genomic Engineering

Genomic Engineering is a hot market now-a-days. A new research report and result by Markets  estimate that the global genome editing market is expected to reach about $3.7 billion by 2020, up from $1.9 billion in 2015. This demand is driven by the growth of biotechnology and pharmaceutical R&D, as well as advances in technology from all over the world. 

1.1 Genomic Screening
1.2 Biomedical Research
1.3 Genome Editing 
1.4 Genome Modifications
1.5 Genomic Engineering & Synthetic Biology
1.6 Gene and Genome Assembly

Biomarkers are  evolving rapidly in the advance of personalized medicine and individual health. The identification & validation of biomarkers in drug discovery, development and in disease prognosis, diagnosis, prevention & treatment play an essential role in the genomic era.

2.1 Immuno-Oncology Biomarkers
2.2 Molecular Biomarkers
2.3 Development of Biomarkers
2.4 Biomarkers in Clinical Research and Development
2.5 Advances of Biomarker Testing
2.6 Genomics biomarkers
2.7 Digital Biomarkers: Biosensors, Wearables, and mHealth
2.8 Biomarkers for Patient Selection
2.9 Biomarkers in Drug Discovery

03. Advances in Cell & Gene Therapy
In this topic we are relating to advances in cell, gene and immune therapies, and their use in the treatment. The tissue-engineered products with unique challenges throughout the development pathway we are discussing.

3.1 Recent Developments in Therapy’s

3.2 Advances in Manufacturing Technologies
3.3 Importance of Innovation & Design
3.4 Automation in Cell and Gene Therapy Manufacturing
3.5 Clinical Grade Production 
3.6 Improvements in Delivery Techniques

04. Manufacturing Innovation & R&D
Manufacturing Innovation is fostered by research and development of technologies in Bio that are aimed at increasing the competitive capability of manufacturing concerns. Broadly speaking, manufacturing-related R&D encompasses improvements in existing methods or processes, or wholly new processes, machines or systems.

4.1 Bioprocessing
4.2 Functional Bio material 
4.3 Appropriate Targeting 
4.4 Technical Challenges 
4.5 Nanotechnology
4.6 Innovative Research
4.7 Novel Technologies
4.8 Gene Therapy Manufacturing

05. Immunogenetics & Transplantation 
Immunogenetics and Transplantation provides specialized diagnostic services for allogeneic transplantation and related research. It provides support for blood, bone marrow, kidney, pancreas, liver, heart, lung, small bowel, and cornea transplantation. Currently Immunogenetics & Transplantation is hot topic of discussion.

5.1 Diagnostic Testing & Research
5.2 Crossmatching
5.3 Scientific Innovations
5.4 Immunogenetics Laboratory Testing
5.5 Organ & Cell Transplantation 

06. Future scope of cell & Gene Therapy
The future of gene therapy holds promise in the treatment of many incurable diseases having no other solutions. At least, the focus for the gene therapy being is only on the incurable diseases. Gene therapy involves a lot of complicated activities which involve cellular trafficking, tissue targeting, safety of vector, delivery of genes to organs, activity of therapeutic protein, etc. The diseases to be treated with gene therapy in the future would mostly be the cardiovascular diseases, hemophilia, monogenic diseases and many related diseases of gene.

6.1 Effective Treatment
6.2 Replacement Therapy
6.3 Future Directions in Therapy 
6.4 Problems with Future Implementation
6.5 The Promise, the Reality
6.6 Modern Genetic Analyses

07.Global Pricing and Market Access
Healthcare affordability and the value of pharmaceutical products have been hot-button issues form many years, and mounting economic pressures and biotechnology advances have made them the focus of a sociopolitical debate because of its complicated procedure

7.1 Overcoming Market Access Barriers
7.2 Reimbursement
7.3 Innovation to Commercialization
7.4 Manufacturing & Logistics
7.5 Challenges & Hurdles

Cell & gene therapies have been at the forefront of medical science in current era because of its promising a hopeful future for many patients suffering from a wide variety of diseases. For over three decades they have been in the headlines for scientific rather than clinical breakthroughs.

8.1 Current State of Gene Therapy
8.2 Potential of Gene Therapy
8.3 Opioid Crisis & Alternatives
8.4 Transforming the Therapy 
8.5 Nuclear Medicine 
8.6 Cell & Gene Therapy Development & Production

Regenerative medicine is the medicine to replace tissue or organs that have been damaged by trauma, disease, or congenital issues, vs. the current clinical strategy that focuses primarily on treating the symptoms of the damaging part. The tools used to realize these outcomes are cellular therapies, tissue engineering, and medical devices and artificial organs.

9.1 Tissue Engineering & Biomaterials
9.2 New Treatments for Major Diseases
9.3 Medical Advancements
9.4 Medical Devices & Artificial Organs
9.5 Cellular Therapies
9.6 Applications of Regenerative Medicine
9.7 Cell & Organ Regeneration
9.8 Nanoscaffolds in Regenerative Medicine

Recent advances strongly suggest that mRNA rather than DNA will be the nucleotide basis for a new class of vaccines and drugs in market.Nucleotide-based vaccines applied to a wide range of infectious and malignant diseases. We focus on recent strategies designed to enhance their function and accuracy. We are concentrating on new strategies and try to forecast future developments that could lead to the real success of nucleic acid vaccines in the prevention and treatment of human disease.

10.1 Immunization 
10.2 Vaccine Production
10.3 Revolution in Medicine
10.4 DNA & RNA-Based Vaccines
10.5 Cancer Vaccine

In Molecular Therapy main target is research on the development of cellular and molecular therapeutics to correct genetic and acquired diseases, but not limited to research on vector development and design, gene transfer and editing, stem cell manipulation, vaccine development but many more...

11.1 Molecular Therapy & unpredicted errors
11.2 Rejuvenation Research
11.3 Enzyme Replacement Therapy
11.4 Combination Therapy
11.5 Methods & Clinical Development
11.6 Oncolytics
11.7 Nucleic Acids

Genetics & Genomic Research we are focusing on novel and significant discoveries in the fields of genetics and genomics, Gene Structure and Organization, Gene Expression, Mutation Detection and Analysis, Linkage Analysis and Genetic Mapping, Physical Mapping, Cytogenetics, Genomic Imaging, Genome Structure and Organization, Disease Association Studies, Comparative Genomics, Molecular Evolution, Genome-Scale Quantitative and Population Genetics, Proteomics, Epigenomics and systems biology.

12.1 Novel Protein Therapeutics
12.2 Bioelectronics in Medicine
12.3 Epigenomics
12.4 Genomics & Big Data
12.5 Computational Biology in Genomic Research
12.6 Pharmacogenomics

In Viral Gene Therapy Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy.

13.1 Vectorology
13.2 Advanced Therapy Manufacturing
13.3 Viral Vectors
13.4 Risk Factors
13.5 Vectors in Gene Therapy
13.6 Ethical Issues & safety 
13.7 Clinical Perspectives

Cell and Gene therapies are poised in market revolutionize medicine and dramatically change the lives of the patients they will treat. As cell and gene manufacturing activity on the rise, the race towards commercialization of cell and gene products has increased. 

14.1 Process of Gene Therapy
14.2 Technological Problems
14.3 Gene Therapy Successes
14.4 Trials & Tribulations
14.5 Global Medical Affairs
14.6 New Technology

Immunotherapy is treatment that uses certain parts of a person’s immune system to fight diseases such as cancer and many other diseases. Immunotherapy works better on many cancers and other autoimmune diseases.

15.1 Combination Immunotherapy
15.2 Immunotherapy Manufacturing
15.3 Diagnostics & Imaging
15.4 Advance in Cancer Immunotherapy
15.5 Immunomodulators 
15.6 Checkpoint Combination

Antibody & protein therapeutics now play a significant role in the treatment and diagnosis of many diseases, this field is continuously evolving with novel and innovative next-generation therapeutics on the horizon in market research

16.1 Bispecific Antibodies
16.2 Antibodies in Oncology & Beyond
16.3 Antibody Drug Conjugates
16.4 Protein Therapeutics
16.5 Protein Design & Engineering

A genetic disease is any disease that is caused by an abnormality in an individual's genome because of mutation in a single base in the DNA or may be chromosome abnormality as the mutation changes the gene's instructions for making a protein, so the protein does not work correctly nor is missing entirely called a genetic disorder.

17.1 Genetic Inheritance
17.2 Multifactorial Inheritance
17.3 Chromosome Abnormalities
17.4 Complex Disorders in Children, Teenagers, and Women
17.5 Mutation
17.6 Teratogenic Problems

Gene cloning is a common practice in molecular biology labs which is used by researchers to create copies of a particular gene for downstream applications or research, such as mutagenesis, sequencing, genotyping or heterologous expression of a protein.
18.1 DNA Cloning
18.2 Epigenetics & Chromatin Analysis 
18.3 Specific Gene Cloning 
18.4 DNA Library
18.5 Protein Production

Stem Cell Research including embryonic stem cells, cancer stem cells, tissue-specific stem cells, we are also focusing on translational and clinical research into stem cell therapeutics and regenerative therapies, developmental studies on stem cells.

19.1 Latest Developments
19.2 Stem Cell Therapy
19.3 Cell Processing

 20.Gene Silencing

 Gene silencing is the regulation of gene expression in a cell to prevent the expression of a certain gene. Gene silencing can occur during either transcription or translation and is often used in research. In particular, methods used to silence genes are being increasingly used to produce therapeutics to combat cancer and diseases, such as infectious diseases and neurodegenerative disorders.

20.1 RNA interference                                          

20.2 Genetic Transformation                                              

20.3 Transcriptional gene silencing

Market Analysis Report

International Conference on Cell & Gene Therapy 2018 to be held during September 10-11 , 2018 Dublin, Ireland with the theme of “Exploring the possibilities in Cell & Gene Therapy” The scope of Gene Therapy Market was valued at $289 million in 2016, and is estimated to reach $2,082 million by 2023, registering a CAGR of 32.4% from 2017 to 2023. With the advancement in technology, the gene therapy market has transformed during the recent few years. Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer.

Key Vendors


 Bluebird Bio



 Genzyme Corporation


Shanghai Sunway Biotech

 Vical Inc.

Human Stem Cells Institute

Shenzhen SiBiono GeneTech


OncoGenex Pharmaceuticals

Sibiono GeneTech Co. Ltd. 

Advantagene Inc.

Oxford BioMedica

Spark Therapeutics, LLC

Altor Bio. Science


SynerGene Therapeutics




AnGes MG, Inc

Cobra Biologics

uniQure N.V.



Vical, Inc

Ark Therapeutics

Gen Vec, Inc

ViroMed Co. Ltd. dba VM BioPharma

Scope & Gene Therapy

01.Overview of the Gene Therapy products in Ophthalmology
02.Pipeline scenario of Gene Therapy products 
03.Competitive landscape of products
04. Pipeline analysis of different phases 
05. Coverage of licensors, collaborators and development partners, deal terms and deal values
06. Highlights of latest developmental technologies 
07. Market drivers and barriers along with the SWOT analysis

Market Challenges 

01. High cost of gene therapy treatment
02. For a full, detailed list, view our report

Market Trend 

01. Favourable government regulations for gene therapy programs
02. For a full, detailed list, view & report
03. Key questions answered in this report
04. What will the market size be in 2021 and what will the growth rate be?
05. What are the key market trends?
06. What is driving this market?
07. What are the challenges to market growth?
08. Who are the key vendors in this market space?     

Key Findings of Study 

01. Gene transfer segment is projected to grow at the highest rate during the analysis period.
02. Oncolytic virotherapy  segment has generated the highest revenue, and is expected to continue its dominance in the future.
03. North America dominated the global cancer gene therapy market, and is projected to continue its dominance in future.
04. China is expected to grow highest in the Asia-Pacific region.
05. Asia-Pacific is expected to be the fastest growing segment during the forecast period.

Highlights of the report 

I)    A complete backdrop analysis, which includes an assessment of the parent market
II)   Important changes in market dynamics
III)  Market segmentation up to the second or third level
IV)  Historical, current, and projected size of the market from the standpoint of both value and volume
V)   Reporting and evaluation of recent industry developments
VI) Market shares and strategies of key players
VII) Emerging niche segments and regional markets
VII)  An objective assessment of the trajectory of the market
VIII) Recommendations to companies for strengthening their foothold in the market


Organizing Committee
OCM Member
Joel Isaías Osorio García
CEO & Founder , Regenerative Medicine
CEO & Founder @ Regenerage Medicine
Mexico, Mexico
OCM Member
Nadia Benkirane Jessel
Research Director at INSERM, Osteoarticular and Dental Regenerative Nanomedicine
University of Stransbourg
Stransbourg, France
OCM Member
Dr.Tony Simula
Manager, Development & Commercialisation at CRC for Cell Therapy Manufacturing, Cell Therapy
University of Adelaide
Adelaide, Australia
OCM Member
Mitchell Sanders
Chief Scientific Officer of Alira Health and Board Member and CEO of an SPV, Firefly Innovations LLC., Cell Biology ,Tissue Engineering,Molecular Biology
Massachusetts Institute of Technology
Portland, USA
OCM Member
Damian Marshall
Head of analytical development for the Cell and Gene Therapy Catapult, Cell Biology ,Cell and Gene Therapy
University of Manchester
Manchester, United Kingdom
OCM Member
Limo Chen
MD at Anderson Cancer Center , Department of Immunology
University of Texas MD Anderson Cancer Center
Houston, USA
OCM Member
Jacopo Meldolesi
First Scientific Director of the Basic Research Department of the San Raffaele Institute, General Pharmacology
Vita-Salute San Raffaele University of Milan
Milan, Italy
OCM Member
Giuseppe Ronzitti
Scientist at Genethon , Gene Therapy ,Neuro Science ,Toxicology
Istituto Italiano di Tecnologia
Genoa, Italy
OCM Member
Alexander Birbrair
Professor, Department of Pathology
Federal University of Minas Gerais
Belo Horizonte, Brazil

Maldron Hotel Newlands Cross

Naas Road, Newlands Cross

Dublin 22



Join The Discussion

Allied Academies Global Conference Directory

Mail us at

Program enquiry
General enquiry
Sponsorship Opportunity
More details about

Terms and Conditions


The organizers holds no responsibilities or liabilities of the personal articles of attendees at the venue against any kind of theft, lost, damage, due to any reason whatsoever. Delegates are entirely responsible for the safety of their own belongings.



No insurance, of any kind, is included along with the registration in any of the events of the organization.



Please note that transportation and parking is the responsibility of the registrant, Allied Academies will not be liable for any actions howsoever related to transportation and parking.



Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party non profit organization and this conference is not associated with any commercial meeting company.


Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference after payment of complete registration fee. Once registration is complete, please contact to request for a personalized letter of invitation, if not received until one month before the scheduled date of event.

All the bank charges applicable during refund will be deducted from the account of participant.


Cancellation Policy

All cancellations or modifications of registration must be made in writing to


Postponement of event

If, due to any reason, Allied academies postpone an event and the participant is unable or unwilling to attend the conference on rescheduled dates, he/she is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.


Transfer of registration

All registrations, after payment of complete registration fee, are transferable to other persons from the same organization, if in case the person is unable to attend the event. Request for transfer of registration must be made by the registered person in writing to . Details must include the full name of replaced new registrant, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.

This cancellation policy was last updated on April 04, 2015.



Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues are not covered under the cancellation policy of Allied academies, including the inability to obtain a visa.


Refund Policy:

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund policies apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overhead charges, following Refund Policy Orders are available:

  • Before 60 days of the conference: Eligible for Full Refund after deduction of $100 towards service Fee.
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund
  • Within 30 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Accommodation Cancellation Policy:

Accommodation Service Providers (Hotels) have their own cancellation policies which are applicable when cancellations are made less than 30 days prior to arrival. If in case the registrant wishes to cancel or amend the accommodation, he/ she is expected to inform the organizing authorities on a prior basis. Allied academies will advise the registrant to ensure complete awareness about the cancellation policy of your accommodation provider, prior to cancellation or modification of their booking.



Authorization Policy

Copyright © 2019-2020 Allied Academies, All Rights Reserved.